Sep. 16 at 3:48 PM
$SUNPHARMA.NSE
Technical Chart Analysis –
$SUN Pharma (Daily)
$SUN Pharma is currently trading around ₹1610, showing signs of stabilization after a corrective decline. On the daily chart, the stock has recently rebounded from the ₹1580 support zone, where buyers stepped in to defend the level.
Moving Averages (MAs): The
$STOCK is trading below its short-term and medium-term moving averages (20, 50, and 100 DMA), which are currently acting as resistance in the ₹1630–1650 zone. A breakout and sustained close above these averages will confirm strength and may open the door for further upside toward ₹1685–1720 levels. On the downside, the 200 DMA near ₹1550 is a strong support level.
Parabolic SAR: Dots are still above the price, signaling that the short-term trend is yet to fully reverse into a confirmed bullish trend. A few more positive candles may flip the SAR below the price, indicating buying momentum.
RSI (Relative Strength Index): RSI is at 49, hovering around the neutral zone, which shows neither overbought nor oversold conditions. This means the stock is at a make-or-break zone, where the next move could set the short-term direction.
MACD (Moving Average Convergence Divergence): The MACD line is below the signal line but flattening, suggesting that downside momentum is slowing. If crossover happens in the coming sessions, it will generate a bullish momentum signal.
Summary View
Support Levels: ₹1580 – ₹1550
Resistance Levels: ₹1630 – ₹1650 (immediate), ₹1685 – ₹1720 (next)
Trend Outlook: Stock is in consolidation with a bias shifting towards recovery. Sustaining above ₹1650 will attract fresh buying interest.
Sun Pharma – Detailed Analysis
1. Micro View (Company Specific)
Technical Setup:
$STOCK is consolidating near ₹1600 with support at ₹1550 and resistance around ₹1650–1685. Momentum indicators suggest a possible rebound if volumes increase.
Fundamentals:
$SUN Pharma remains India’s largest pharma
$COMPANY with strong leadership in chronic therapies, dermatology, and specialty drugs in the US market. Its robust pipeline of specialty products and acquisitions in emerging markets support long-term growth.
Recent Performance: Q1 FY26 results showed steady revenue growth, led by US specialty business and domestic formulations. Margins improved slightly due to cost efficiency measures.
2. Macro View (Sector & Economy)
Sector Trends:
$INDIAN pharma sector is benefiting from increasing healthcare demand, patent expiries in the US, and a rising focus on generics + specialty products.
Global Outlook: With the US FDA approvals becoming more frequent and demand for low-cost generics rising, Indian pharma companies like Sun Pharma are well-positioned.
Risks: Pricing pressure in US generics, regulatory hurdles, and currency fluctuations may impact near-term performance.
3.Upcoming Events & Possible Impact
USFDA Inspections/Approvals: Any new approval for specialty products in dermatology or oncology will likely boost sentiment and stock price.
Quarterly Results (Q2 FY26): If
$SUN Pharma continues its growth momentum in the US + Indian markets, the stock could see a strong re-rating.
Budget / Policy Announcements: Government’s push on healthcare spending and incentives for domestic manufacturing (PLI schemes) may provide long-term tailwinds.
Global Events: Any major shift in US pharma pricing policy or patent wins/losses could directly impact earnings visibility.
Investment View
Short Term (1–3 months): Consolidation likely in ₹1550–1650 range; breakout above ₹1650 may target ₹1685–1720.
Medium Term (3–6 months): Stable outlook with growth driven by US specialty products; price target zone ₹1750–1820.
Long Term (1+ year): Strong structural story; leadership in pharma, R&D pipeline, and global expansion may take the stock above ₹2000+.
Disclaimer
This analysis is prepared for educational and informational purposes only. It should not be considered as investment advice or a buy/sell recommendation. Stock market investments are subject to risks. Please consult your financial advisor before making any investment decisions.
Disclosure
We, at Investogainer Research, are a SEBI Registered Research Analyst (INH000012856) and also listed with BSE (Code: 5845). We do not hold any personal or family positions in this stock. Our views are unbiased and based on technical and fundamental research.
